JW (Cayman) Therapeutics Co. Ltd (HKG:2126)
Hong Kong · Delayed Price · Currency is HKD 5.08
-0.05 (-0.97%)
Sep 11, 2025, 3:45 PM HKT
HKG:2126 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2020 |
Operating Revenue | 177.75 | 158.22 | 173.86 | 145.7 | 30.8 | - | Upgrade |
| 177.75 | 158.22 | 173.86 | 145.7 | 30.8 | - | Upgrade | |
Revenue Growth (YoY) | 2.79% | -9.00% | 19.32% | 373.11% | - | - | Upgrade |
Cost of Revenue | 79.06 | 80.9 | 85.64 | 86.95 | 21.75 | - | Upgrade |
Gross Profit | 98.69 | 77.32 | 88.22 | 58.76 | 9.05 | - | Upgrade |
Selling, General & Admin | 215.76 | 260.48 | 253.24 | 370.64 | 372.25 | 244.56 | Upgrade |
Research & Development | 224.02 | 282.99 | 413.62 | 407.82 | 414.4 | 225.22 | Upgrade |
Other Operating Expenses | -8.54 | -7.12 | -8.5 | -22.53 | -5.89 | -1.92 | Upgrade |
Operating Expenses | 431.25 | 536.35 | 658.37 | 755.93 | 780.76 | 467.86 | Upgrade |
Operating Income | -332.56 | -459.03 | -570.15 | -697.18 | -771.72 | -467.86 | Upgrade |
Interest Expense | -12.41 | -12.22 | -12.42 | -6.79 | -2.69 | -0.77 | Upgrade |
Interest & Investment Income | 27.56 | 28.43 | 34.03 | 16.54 | 8.3 | 3.44 | Upgrade |
Currency Exchange Gain (Loss) | -15.4 | -15.6 | -37.32 | -158.54 | 14.84 | 28.9 | Upgrade |
Other Non Operating Income (Expenses) | - | - | - | - | 51.15 | -34.84 | Upgrade |
EBT Excluding Unusual Items | -332.81 | -458.42 | -585.86 | -845.97 | -700.12 | -471.13 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | -0.93 | -0.17 | -0.12 | - | Upgrade |
Asset Writedown | -284.86 | -132.26 | -181.21 | - | - | - | Upgrade |
Other Unusual Items | 0.05 | 0.05 | - | - | -2.09 | -1,193 | Upgrade |
Pretax Income | -617.62 | -590.62 | -768 | -846.14 | -702.33 | -1,664 | Upgrade |
Net Income | -617.62 | -590.62 | -768 | -846.14 | -702.33 | -1,664 | Upgrade |
Net Income to Common | -617.62 | -590.62 | -768 | -846.14 | -702.33 | -1,664 | Upgrade |
Shares Outstanding (Basic) | 415 | 414 | 412 | 410 | 400 | 132 | Upgrade |
Shares Outstanding (Diluted) | 415 | 414 | 412 | 410 | 400 | 132 | Upgrade |
Shares Change (YoY) | 0.58% | 0.51% | 0.35% | 2.59% | 203.07% | 102.92% | Upgrade |
EPS (Basic) | -1.49 | -1.43 | -1.87 | -2.06 | -1.76 | -12.61 | Upgrade |
EPS (Diluted) | -1.49 | -1.43 | -1.87 | -2.06 | -1.76 | -12.61 | Upgrade |
Free Cash Flow | - | -338.67 | -410.83 | -613.6 | -634.29 | -385.24 | Upgrade |
Free Cash Flow Per Share | - | -0.82 | -1.00 | -1.50 | -1.59 | -2.92 | Upgrade |
Gross Margin | 55.52% | 48.87% | 50.74% | 40.33% | 29.37% | - | Upgrade |
Operating Margin | -187.09% | -290.13% | -327.94% | -478.49% | -2505.82% | - | Upgrade |
Profit Margin | -347.47% | -373.30% | -441.74% | -580.73% | -2280.51% | - | Upgrade |
Free Cash Flow Margin | - | -214.05% | -236.30% | -421.13% | -2059.57% | - | Upgrade |
EBITDA | -266.23 | -391.09 | -492.69 | -629.53 | -738.7 | -454.04 | Upgrade |
EBITDA Margin | -149.78% | -247.18% | -283.39% | - | - | - | Upgrade |
D&A For EBITDA | 66.33 | 67.95 | 77.46 | 67.65 | 33.01 | 13.82 | Upgrade |
EBIT | -332.56 | -459.03 | -570.15 | -697.18 | -771.72 | -467.86 | Upgrade |
EBIT Margin | -187.09% | -290.13% | - | - | - | - | Upgrade |
Advertising Expenses | - | 97.18 | 48.39 | 77.39 | 70.12 | 5.66 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.